GlassScriptPhysician profile
Leslie Ross
NPI 1447640669
$4,490.47
in general payments reported to CMS, 2019-2025
38 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $461 · 2022: $667 · 2023: $954 · 2024: $1,301 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,338 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,337.60 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,243.83 | 2021-2025 | |
| Amgen INC. | $561.17 | 2021-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $288.73 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Exact Sciences Corporation | $240.78 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Supernus Pharmaceuticals, INC. | $211.68 | 2024 | Qelbree, Xyosted |
| Otsuka America Pharmaceutical, INC. | $202.88 | 2022-2025 | Rexulti, Abilify Maintena |
| Astrazeneca Pharmaceuticals LP | $188.60 | 2022-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $175.07 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $131.27 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $119.02 | 2024-2025 | Auvelity |
| Seagen INC. | $100.51 | 2022-2023 | Tukysa, Adcetris |
| Pfizer INC. | $80.90 | 2023-2025 | |
| Antares Pharma, INC. | $70.45 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Biohaven Pharmaceuticals, INC. | $68.83 | 2021 | |
| Abbott Laboratories | $67.14 | 2021-2025 | Freestyle Libre |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $62.32 | 2023-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $57.03 | 2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $55.73 | 2024-2025 | Iclusig |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.19 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.72 | 2022-2025 | |
| Ardelyx, INC. | $43.81 | 2025 | Ibsrela |
| Alfasigma USA, INC. | $42.49 | 2021-2022 | |
| Eisai INC. | $38.60 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $36.96 | 2022-2023 | Nexletol |
| Genentech USA, INC. | $35.36 | 2021 | |
| Idorsia Pharmaceuticals US INC | $33.64 | 2022-2024 | Quviviq |
| Ibsa Pharma INC. | $24.99 | 2024 | Licart, Flector, Tirosint |
| Mycovia Pharmaceuticals, INC. | $23.71 | 2022 | |
| Allergan, INC. | $23.66 | 2021 | |
| Noven Therapeutics, LLC | $21.57 | 2024 | Xelstrym |
| Tris Pharma INC | $19.84 | 2023 | Dyanavel Xr |
| Lundbeck LLC | $18.65 | 2024 | Rexulti |
| Halozyme INC | $18.39 | 2023 | |
| Jazz Pharmaceuticals INC. | $18.30 | 2021 | |
| Merck Sharp & Dohme LLC | $16.75 | 2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $15.70 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.23 | 2024 | Austedo Xr |
| Ethicon US, LLC | $14.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.